Regulatory of Personalized medicine

The FDA is  already started to take initiatives to integrate personalized medicine into their regulatory policies.They developed a report in October 2013 entitled Paving the Way for Personalized Medicine FDAs role in a New Era of Medical Product Development in which they outlined steps they would have to take to integrate genetic and biomarker information for clinical use and drug development. They determined that they would have to develop specific regulatory science standards, research methods, reference material and other tools in order to incorporate personalized medicine into their current regulatory practices. For example, they are working on a genomic reference library for regulatory agencies to compare and test the validity of different sequencing platforms in an effort to uphold reliability.

  • FDA and Personalized medicine
  • Regulatory aspects of pharmacogenetics
  • FDA and predictive medicine
  • FDA and validation of biomarkers

Related Conference of Regulatory of Personalized medicine

June 20-21, 2018

15th European Pathology Congress

| Paris, France
June 25-26, 2018

15th Congress on Pathology and Cancer Research

Vancouver, Canada
August 29-30, 2018

4th International Conference on Cytopathology & Histopathology

Boston | Massachusetts | USA
August 31 - September 01, 2018

International Conference and Expo on Dermatopathology and Skin Diagnosis

Toronto, Canada
September 17-18,2018

16th Annual Conference on Laboratory Medicine & Pathology

Kuala Lumpur, Malaysia
Sep 17-18, 2018

16th Asia Pacific Pathology Congress

Tokyo, Japan
October 18-19, 2018

Biology and Pathology of Infectious Diseases Conference

Helsinki, Finland

Regulatory of Personalized medicine Conference Speakers

Recommended Sessions

Related Journals

Are you interested in